[Skip to Navigation]
Brief Report
December 8, 2021

Evaluation of a Case Series of Patients With Palmoplantar Pustulosis in the United States

Author Affiliations
  • 1Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 2Department of Internal Medicine, Memorial Hospital West, Pembroke Pines, Florida
  • 3Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia
  • 4Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia
JAMA Dermatol. 2022;158(1):68-72. doi:10.1001/jamadermatol.2021.4635
Key Points

Question  What are the patient characteristics and disease course of adults with palmoplantar pustulosis in the US?

Findings  In this case series of 197 adults with palmoplantar pustulosis, 35.5% of patients were treated with systemic therapies, and more than 20 different systemic therapies were used. In 128 patients with at least 6 months of follow-up, a median of 3.7 dermatology visits per year were reported; 18.8% of patients had 5 or more visits during the study period.

Meaning  Palmoplantar pustulosis was associated with persistent symptoms, continued health care utilization, and a lack of consensus regarding effective treatments, emphasizing the unmet medical need in this population.

Abstract

Importance  Palmoplantar pustulosis (PPP) is a is a chronic, orphan disease with limited epidemiological data.

Objective  To describe the clinical characteristics, treatments, longitudinal disease course, and health care utilization in adults with PPP across the US.

Design, Setting, and Participants  This retrospective, longitudinal case series from 20 academic dermatology practices in the US included a consecutive sample of 197 adults who met the European Rare and Severe Psoriasis Expert Network consensus definition for PPP between January 1, 2007, and December 31, 2018. Data analysis was performed June 2020 to December 2020.

Main Outcomes and Measures  The primary outcome was to describe the patient characteristics, associated medical comorbidities, treatment patterns, complications, and PPP-specific health care utilization.

Results  Of 197 patients, 145 (73.6%) were female, and the mean (SD) age at presentation was 53.0 (12.6) years, with a mean (SD) follow-up time of 22.1 (28.0) months. On initial presentation, 95 (48.2%) patients reported skin pain, and 39 (19.8%) reported difficulty using hands and/or feet. Seventy patients (35.5%) were treated with systemic treatments, and use of more than 20 different systemic therapies was reported. In patients with at least 6 months of follow-up (n = 128), a median (IQR) of 3.7 (4-10) dermatology visits per year were reported; 24 (18.8%) patients had 5 or more visits during the study period.

Conclusions and Relevance  In this case series, PPP was associated with persistent symptoms, continued health care utilization, and a lack of consensus regarding effective treatments, emphasizing the unmet medical need in this population. Additional research is necessary to understand treatment response in these patients.

Add or change institution
×